Comparision of the effects of rimazolam methylphenidate and propofol in the treatment of MECT

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300068779

Enrollment

Unknown

Registered

2023-02-28

Start date

2023-03-01

Completion date

Unknown

Last updated

2023-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Modified electroconvulsive therapy

Interventions

Group A:Rimazolam Methylphenidate

Group B:Propofol

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: ?Meeting the indications for MECT treatment ?ASA classification I-II ?Patient's family agreed and signed the study informed conset form

Exclusion criteria

Exclusion criteria: ?Combined with serious physical illness,such as uncontrolled hypertension,coronary artery disease,asthma attacks,severe respiratory disease,abnormal liver and kidney function,airway difficulties,craniosynostosis ?Patients with a history of epilepsy ?Allergy to the drug used in the study ?Patients with contraindications to MECT

Design outcomes

Primary

Measure	Time frame
Breathing recovery time;	—

Secondary

Measure	Time frame
Wake up time after stopping medication;Sedation induction time;Twitch power;Duration of convulsive seizures;The hemodynamic indicators included heart rate and arterial pressure;	—

Countries

China

Contacts

Public ContactXia Xiaoqiong

Department of Anesthesiology, Chaohu Hospital Affiliated to Anhui Medical University

xxq2366833@sina.com13966386669

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026